Autopsy report · NCT00687674

Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

“Due to study design (and toxicity), this trial closed to accrual prior to opening the phase II portion.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 3 years 3 months before it stopped.
• 13 participants enrolled.
• Results were posted on the registry 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Mayo Clinic

Sponsor type

University, hospital or other

Conditions

Multiple Myeloma and Plasma Cell Neoplasm

Interventions

dexamethasone; sorafenib tosylate; Lenalidomide

Participants

13

Sites

1

Countries

United States

Trials that died the same way

• A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)
  “Due to safety findings in ongoing Phase 2 trials.” (72% match in meaning)
• Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer
  “Trial did not move to Phase II portion due to poor tolerance of treatment” (70% match in meaning)
• Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib
  “Enrollment held for toxicity evaluation; then closed due to competing trial” (69% match in meaning)
• Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer
  “The study used a two-stage design. After stage one, the study was terminated due to excess toxicity.” (69% match in meaning)
• Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia
  “This study was terminated early due to other competing trials, therefore did not go on to the Phase II portion of the study.” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.